NEW GUIDELINES for cervical cancer screening issued last year are fueling strong growth in the sales of Digene Corporation’s HPV test. For its fiscal second quarter that ended on December 31, 2004, Digene reported sales of $27.0 million. That’s a 28% increase from Digene’s sales of $21.1 million for its second quarter last year. HPV …
Evolution in Pap Marketplace Shows Impact of New Guidelines Read More »
